Ipsen S.A. (IPSEY), a specialty-care biopharmaceutical company, on Thursday reported higher earnings for 2025, supported by stronger sales performance.
Net income attributable to shareholders climbed to €443.5 million or €5.32 per share from €345.9 million or €4.15 per share in 2024.
Excluding one-time items, core profit rose to €1.008 billion €12.09 per share from €856.3 million or €10.27 per share last year.
Operating profit increased to €625.9 million compared with €496.7 million a year ago, while core operating income grew to €1.294 billion from €1.109 billion.
Sales rose 8.1% to €3.676 billion from €3.401 billion a year earlier. On a constant currency basis, sales grew 10.9%.
Sales growth was driven by the three therapeutic areas — Oncology up 4.1%, Rare Disease up 102.5% and Neuroscience up 9.7% — as well as Somatuline, which increased 4.3%.
For 2026, the company expects sales to grow more than 13% at constant currency.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.